Author

María Dolores Martín-Arranz

IMPACT OF THE HLA-DQA1*05 ALLELE ON LOSS OF RESPONSE AND PRESENCE OF ANTI-DRUG ANTIBODIES TO USTEKINUMAB IN CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS
IMPACT OF THE HLA-DQA1*05 ALLELE ON LOSS OF RESPONSE AND PRESENCE OF ANTI-DRUG ANTIBODIES TO USTEKINUMAB IN CROHN’S DISEASE AND ULCERATIVE COLITIS PATIENTS

María Dolores Martín-Arranz  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

María Dolores Martín-Arranz  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

María Dolores Martín-Arranz  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

María Dolores Martín-Arranz  et al.

UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE
UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

María Dolores Martín-Arranz  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

María Dolores Martín-Arranz  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

María Dolores Martín-Arranz  et al.

ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE
ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

María Dolores Martín-Arranz  et al.

ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE
ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE

María Dolores Martín-Arranz  et al.

COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Dolores Martín-Arranz  et al.

CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE
CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE

María Dolores Martín-Arranz  et al.

ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE
ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE

María Dolores Martín-Arranz  et al.

INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE
INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE

María Dolores Martín-Arranz  et al.

SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION
SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION

María Dolores Martín-Arranz  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

María Dolores Martín-Arranz  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

María Dolores Martín-Arranz  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

María Dolores Martín-Arranz  et al.

MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU
MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU

María Dolores Martín-Arranz  et al.

Item 1 - 20 / 25
1
2